Certara Inc (CERT)

$11.18

-0.23

(-2.02%)▲

Live

Performance

  • $11.11
    $11.38
    $11.18
    downward going graph

    0.63%

    Downside

    Day's Volatility :2.37%

    Upside

    1.76%

    downward going graph
  • $10.35
    $19.87
    $11.18
    downward going graph

    7.42%

    Downside

    52 Weeks Volatility :47.91%

    Upside

    43.73%

    downward going graph

Returns

PeriodCertara IncSector (Health Care)Index (Russel 2000)
3 Months
-31.18%
3.6%
0.0%
6 Months
-29.39%
10.2%
0.0%
1 Year
-13.95%
19.6%
0.0%
3 Years
-70.42%
16.8%
-23.0%

Highlights

Market Capitalization
1.9B
Book Value
$6.49
Earnings Per Share (EPS)
-0.5
Wall Street Target Price
16.28
Profit Margin
-21.64%
Operating Margin TTM
-9.69%
Return On Assets TTM
0.35%
Return On Equity TTM
-7.35%
Revenue TTM
363.6M
Revenue Per Share TTM
2.28
Quarterly Revenue Growth YOY
3.2%
Gross Profit TTM
203.1M
EBITDA
70.7M
Diluted Eps TTM
-0.5
Quarterly Earnings Growth YOY
-0.14
EPS Estimate Current Year
0.41
EPS Estimate Next Year
0.51
EPS Estimate Current Quarter
0.1
EPS Estimate Next Quarter
0.11

Analyst Recommendation

Hold
    47%Buy
    52%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Certara Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
7
Hold
9
9
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 45.62%

Current $11.18
Target $16.28

Company Financials

FY18Y/Y Change
Revenue
163.7M
-
Net Income
-33.3M
-
Net Profit Margin
-20.31%
-
FY19Y/Y Change
Revenue
208.5M
↑ 27.36%
Net Income
-8.9M
↓ 73.16%
Net Profit Margin
-4.28%
↑ 16.03%
FY20Y/Y Change
Revenue
243.5M
↑ 16.79%
Net Income
-49.4M
↑ 453.41%
Net Profit Margin
-20.28%
↓ 16.0%
FY21Y/Y Change
Revenue
286.1M
↑ 17.48%
Net Income
-13.3M
↓ 73.14%
Net Profit Margin
-4.64%
↑ 15.64%
FY22Y/Y Change
Revenue
335.6M
↑ 17.32%
Net Income
14.7M
↓ 211.04%
Net Profit Margin
4.39%
↑ 9.03%
FY23Y/Y Change
Revenue
354.3M
↑ 5.57%
Net Income
-55.4M
↓ 475.79%
Net Profit Margin
-15.62%
↓ 20.01%
Q1 FY23Q/Q Change
Revenue
90.3M
↑ 4.23%
Net Income
1.4M
↓ 85.2%
Net Profit Margin
1.5%
↓ 9.09%
Q2 FY23Q/Q Change
Revenue
90.5M
↑ 0.17%
Net Income
4.7M
↑ 246.54%
Net Profit Margin
5.2%
↑ 3.7%
Q3 FY23Q/Q Change
Revenue
85.6M
↓ 5.39%
Net Income
-49.0M
↓ 1140.48%
Net Profit Margin
-57.22%
↓ 62.42%
Q4 FY23Q/Q Change
Revenue
88.0M
↑ 2.84%
Net Income
-12.5M
↓ 74.56%
Net Profit Margin
-14.15%
↑ 43.07%
Q1 FY24Q/Q Change
Revenue
96.7M
↑ 9.82%
Net Income
-4.7M
↓ 62.4%
Net Profit Margin
-4.85%
↑ 9.3%
Q2 FY24Q/Q Change
Revenue
93.3M
↓ 3.46%
Net Income
-12.6M
↑ 168.5%
Net Profit Margin
-13.48%
↓ 8.63%
FY18Y/Y Change
Total Assets
1.1B
-
Total Liabilities
558.7M
-
FY19Y/Y Change
Total Assets
1.0B
↓ 1.37%
Total Liabilities
545.0M
↓ 2.45%
FY20Y/Y Change
Total Assets
1.3B
↑ 22.4%
Total Liabilities
447.3M
↓ 17.94%
FY21Y/Y Change
Total Assets
1.5B
↑ 19.09%
Total Liabilities
469.9M
↑ 5.06%
FY22Y/Y Change
Total Assets
1.6B
↑ 4.05%
Total Liabilities
493.3M
↑ 4.98%
FY23Y/Y Change
Total Assets
1.6B
↓ 0.62%
Total Liabilities
516.3M
↑ 4.67%
Q1 FY23Q/Q Change
Total Assets
1.6B
↓ 0.39%
Total Liabilities
481.7M
↓ 2.34%
Q2 FY23Q/Q Change
Total Assets
1.6B
↑ 0.35%
Total Liabilities
475.0M
↓ 1.38%
Q3 FY23Q/Q Change
Total Assets
1.5B
↓ 2.89%
Total Liabilities
475.1M
↑ 0.01%
Q4 FY23Q/Q Change
Total Assets
1.6B
↑ 2.38%
Total Liabilities
516.3M
↑ 8.68%
Q1 FY24Q/Q Change
Total Assets
1.5B
↓ 1.33%
Total Liabilities
488.0M
↓ 5.48%
Q2 FY24Q/Q Change
Total Assets
1.5B
↓ 0.18%
Total Liabilities
496.2M
↑ 1.68%
FY18Y/Y Change
Operating Cash Flow
11.6M
-
Investing Cash Flow
-73.9M
-
Financing Cash Flow
57.3M
-
FY19Y/Y Change
Operating Cash Flow
38.0M
↑ 228.03%
Investing Cash Flow
-9.5M
↓ 87.12%
Financing Cash Flow
-8.5M
↓ 114.82%
FY20Y/Y Change
Operating Cash Flow
44.8M
↑ 17.84%
Investing Cash Flow
-8.6M
↓ 9.51%
Financing Cash Flow
208.2M
↓ 2552.75%
FY21Y/Y Change
Operating Cash Flow
60.4M
↑ 34.76%
Investing Cash Flow
-269.9M
↑ 3034.25%
Financing Cash Flow
123.4M
↓ 40.74%
FY22Y/Y Change
Operating Cash Flow
92.5M
↑ 53.25%
Investing Cash Flow
-27.8M
↓ 89.69%
Financing Cash Flow
-7.4M
↓ 105.97%
Q1 FY23Q/Q Change
Operating Cash Flow
10.0M
↓ 71.94%
Investing Cash Flow
-2.7M
↓ 78.32%
Financing Cash Flow
-850.0K
↓ 12.19%
Q2 FY23Q/Q Change
Operating Cash Flow
18.1M
↑ 81.36%
Investing Cash Flow
-11.7M
↑ 329.55%
Financing Cash Flow
-6.4M
↑ 655.29%

Technicals Summary

Sell

Neutral

Buy

Certara Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Certara Inc
Certara Inc
5.06%
-29.39%
-13.95%
-70.42%
-70.04%
Solventum Corp
Solventum Corp
5.08%
18.7%
6.63%
6.63%
6.63%
Tempus Ai
Tempus Ai
-10.87%
22.58%
22.58%
22.58%
22.58%
Veeva Systems Inc.
Veeva Systems Inc.
4.87%
11.18%
13.42%
-31.95%
52.57%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
0.51%
8.34%
42.74%
51.0%
51.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Certara Inc
Certara Inc
100.92
NA
NA
0.41
-0.07
0.0
NA
6.49
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Tempus Ai
Tempus Ai
NA
NA
NA
-2.41
0.0
0.0
NA
0.64
Veeva Systems Inc.
Veeva Systems Inc.
57.72
57.72
1.25
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
26.25
26.25
2.37
4.25
0.21
0.06
0.0
17.08
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Certara Inc
Certara Inc
Hold
$1.9B
-70.04%
100.92
-21.64%
Solventum Corp
Solventum Corp
Hold
$10.8B
6.63%
NA
15.73%
Tempus Ai
Tempus Ai
NA
$7.9B
22.58%
NA
-121.04%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$35.1B
52.57%
57.72
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$41.7B
51.0%
26.25
8.1%

Insights on Certara Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 96.65M → 93.31M (in $), with an average decrease of 3.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.68M → -12.57M (in $), with an average decrease of 168.5% per quarter

  • Vs GEHC

    In the last 1 year, Ge Healthcare Technologies Inc. has given 42.6% return, outperforming this stock by 58.1%

Institutional Holdings

  • BlackRock Inc

    8.34%

  • Vanguard Group Inc

    7.77%

  • Mubadala Investment Company PJSC

    5.98%

  • Baillie Gifford & Co Limited.

    5.19%

  • Wasatch Advisors LP

    4.58%

  • Geneva Capital Management

    3.40%

Company Information

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.

Organization
Certara Inc
Employees
1338
CEO
Dr. William F. Feehery Ph.D.
Industry
Healthcare

Discover More

FAQs